Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.
about
Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population.Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence RatesReducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysisHidden hazards of HCV transmission.Emerging technologies for the clinical microbiology laboratory.Evaluation of the Gen-Probe Aptima HIV-1 RNA qualitative assay as an alternative to Western blot analysis for confirmation of HIV infection.Automated nucleic acid amplification testing in blood banks: An additional layer of blood safety.Sensitive detection assays for influenza RNA do not reveal viremia in US blood donorsIndividual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safetyMolecular beacon probes-base multiplex NASBA Real-time for detection of HIV-1 and HCV.Expanded criteria donors.Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Qualitative human immunodeficiency virus RNA analysis of dried blood spots for diagnosis of infections in infantsExposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection.Diagnosis and Management of Hepatitis C Virus Infection.Evaluation of pooling strategies for acute HIV-1 infection screening using nucleic acid amplification testing.Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types.Detection of HIV-1 in alternative specimen types using the APTIMA HIV-1 RNA Qualitative AssayDesign and development of an in-house multiplex RT-PCR assay for simultaneous detection of HIV-1 and HCV in plasma samples.Design and Development of a Multiplex Real-Time PCR Assay for Detection of HIV-1 and HCV Using Molecular BeaconsProcleix Ultrio transcription-mediated amplification vs. serological blood screening in south-western Greece.Clinical evaluation of an HIV-1 and HCV assay and demonstration of significant reduction of the HCV detection window before seroconversion.Clinical significance of nondiscriminated reactive results with the Chiron Procleix HIV-1 and HCV assay.Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections.Dynamics of viremia in early hepatitis C virus infection.Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection.Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population.Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors.Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system.Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia.The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy.Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.Significance of the signal-to-cutoff ratios of anti-hepatitis C virus enzyme immunoassays in screening of Chinese blood donors.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.HCV viral load in anti-HCV-reactive donors and infectivity for their recipients.
P2860
Q27471272-96E2ABFC-1D83-43AC-82ED-0EE8CEB3E200Q27485369-E78D7B40-FF7B-450A-A1D4-61DD012B3CFCQ33882186-2914939B-1D6B-4B0A-A48D-827564F9AE09Q34114816-1D9A6B26-28D6-4B5E-9514-6CD158222BDFQ34297668-D66F44E5-515D-4D61-9BC2-2F38B85AFFE7Q35067057-13DA4291-7498-4B66-B5CD-CC9EDBAD7521Q35119946-470412CB-58FA-4AEE-963D-7EAD124FA843Q35765991-BBCB887F-B0B7-4C5C-9528-340763200AC8Q36034896-45914720-B540-47E7-B3CD-0354E030D798Q36211386-60162A28-4A39-4911-80CC-849E4B74A4EEQ36733650-4266C3AC-6934-4821-B856-705E0D0D0082Q36779718-57B76906-A180-4D9A-BBB6-9AFF6F8EC51BQ37051563-5DAD8133-02BD-437B-AD1C-8CFB0A7A64C9Q37502673-4C3120DF-990E-4194-810F-FAA9724B486DQ38105969-AA0A2926-605A-4DC4-80EA-422EC9B54B32Q38327430-8620210A-BA98-4358-826B-76949A9F79B7Q38630017-D83B9716-CD91-4DEC-A9AC-1CA9D513E037Q40168269-8C276A73-A837-4821-A50A-F438BE972ACFQ41789791-72C12443-D076-4899-B401-33F8C8FDF8BCQ42228568-F0099180-A852-4A2C-A11A-DBE6C9D34F42Q42272705-48586E2A-8709-4606-8418-D79F241709E2Q42977683-53CDF4A7-D303-47D0-BB05-3380BAFF6529Q42982079-1C9EBA1B-6449-43E5-831F-BDEA14D7D54AQ42982082-BAB7AB6E-1834-4079-847A-AF0BBAFDC159Q42984718-404305C1-718F-4CE2-BE98-D7AF79EC205FQ42992916-13076BDA-91FF-4308-8DA4-1F881AC34E80Q42997283-8E57CF94-A36B-4970-9A9C-D4F46420B24FQ42997619-C2F5BD6D-F93A-4A5E-8CE3-B06AC8908158Q42998919-EAA7D439-CB84-4D97-8FB8-FE54CD885A16Q43000025-5F361724-6F09-4ED4-9DBB-93C2EF0CC25BQ43034619-3D8FA4B5-3A7C-4E20-8C9F-EEFA9F9BD524Q43040836-67EC02B0-E4EA-4875-B2E5-C0E1D10C642BQ43042208-947956B8-E7B7-441B-8D0A-FFE5144D6FB2Q43047486-8C42C6EF-D344-42D2-9D58-46FACCEDC07DQ43047736-66949E5B-25DD-4F93-B543-D91FA2439F8CQ43047996-F5D478DA-9C78-4A55-B8C4-BD8992831678Q44496064-4681B1C7-A584-457F-B4F1-B8059C348381Q44931522-DC12C44A-FAE3-48C1-963E-6DC05834D73DQ45409042-BABE1B12-B145-4EAA-A0F0-FD8D0CE37AFCQ46472229-2D68679F-DDE7-42FF-B74D-593F7843DBBF
P2860
Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Highly Sensitive Multiplex Ass ...... pe 1 and Hepatitis C Virus RNA
@nl
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@ast
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@en
type
label
Highly Sensitive Multiplex Ass ...... pe 1 and Hepatitis C Virus RNA
@nl
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@ast
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@en
prefLabel
Highly Sensitive Multiplex Ass ...... pe 1 and Hepatitis C Virus RNA
@nl
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@ast
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@en
P2093
P2860
P1476
Highly sensitive multiplex ass ...... e 1 and hepatitis C virus RNA.
@en
P2093
C Giachetti
J M Linnen
K Gillotte-Taylor
M Ho-Sing-Loy
M K McCormick
S H McDonough
P2860
P304
P356
10.1128/JCM.40.7.2408-2419.2002
P407
P577
2002-07-01T00:00:00Z